Olyth
Home
About
Terms
Privacy
Citius Pharmaceuticals, Inc. (CTXR) Stock Price, Chart & News | Olyth
CTXR
Citius Pharmaceuticals, Inc.
$0.59
+$0.02 (+3.81%)
Today
+$0.01 (+1.46%)
After Hours
1d
5d
1mo
6mo
1y
5y
max
Key Statistics
Market cap
16M
Price-Earnings ratio
-0.72
Dividend yield
—
Average volume
191.08K
High today
$0.61
Low today
$0.56
Open price
$0.56
Volume
71.01K
52 Week high
$2.19
52 Week low
$0.48
Company Profile
Recent News
Company Profile
No profile description available.
Recent News
PR Newswire
6/1/2026
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Insider Monkey
5/24/2026
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
PR Newswire
5/26/2026
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
PR Newswire
5/15/2026
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
PR Newswire
5/15/2026
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
PR Newswire
4/24/2026
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
PR Newswire
4/24/2026
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
PR Newswire
4/29/2026
Citius Oncology Ships First International Order of LYMPHIR™ to Europe